Our pipeline consists of highly differentiated molecules that were designed and optimized to effectively block key oncogenic pathways in hematological malignancies and solid tumors to address important unmet needs in patients with cancer.
We have developed a diverse pipeline consisting of four distinct programs that utilized three unique small molecule modalities, enzyme inhibition, disruption of protein-protein interactions, and targeted protein degradation.
Our differentiation strategy is to design and optimize each of our small molecule therapeutics to possess specific properties that have the potential to benefit patients:
- For PRT2527 (CDK9), we optimized for superior selectivity over previously developed CDK9i to improve tolerability
- For PRT1419 (MCL-1), we optimized the PK profile that allows high target engagement for a short duration to avoid cardiotoxicity
- For PRT3645 (CDK4/6), we focused on high selectivity and improved tissue penetration with low drug/drug interaction
- For PRT3789 (SMARCA2), we sought high selectivity over SMARCA4 to elicit synthetic lethality using a targeted protein degrader approach
| Program | Cancer Indications | Discovery | Phase 1 | Phase 2/3 | Areas of Clinical Focus |
|---|---|---|---|---|---|
| PR-01 | |||||
| CDK9 PRT2527 |
Selected solid and hematologic malignancies | CLL, Lymphoma | |||
| MCL1 PRT1419 |
Selected hematologic malignancies and solid tumors | AML, CLL, Lymphoma | |||
| CDK4/6 PRT3645 |
Selected solid tumors | Breast Cancer, Gliomas, HNSCC, Lung Cancer, and Endometrial cancers | |||
| SMARCA2 PRT3789 (IV) |
Multiple genomically-selected cancers | SMARCA4 mutated NSCLC and Other cancers | |||
| SMARCA2 (Oral) |
Multiple genomically-selected cancers | SMARCA4 mutated NSCLC and Other cancers | |||
| New Programs (Multiple Targets) |
Selected solid and hematologic malignancies | Solid Tumors Heme Malignancies | |||
| PR-01 | CDK9 PRT2527 | |
| Selected solid and hematologic malignancies | ||
Discovery Phase 1 Phase 2 | ||
| Areas of Focus: CLL, Lymphoma | ||
| MCL1 PRT1419 | ||
| Selected hematologic malignancies and solid tumors | ||
Discovery Phase 1 Phase 2 | ||
| Areas of Focus: AML, CLL, Lymphoma | ||
| CDK4/6 PRT3645 | ||
| Selected solid tumors | ||
Discovery Phase 1 Phase 2 | ||
| Areas of Focus: Breast Cancer, Gliomas, HNSCC, Lung Cancer, and Endometrial cancers | ||
| SMARCA2 PRT3789 (IV) | ||
| Multiple genomically-selected cancers | ||
Discovery Phase 1 Phase 2 | ||
| Areas of Focus: SMARCA4 mutated NSCLC and Other cancers | ||
| SMARCA2 (Oral) | ||
| Multiple genomically-selected cancers | ||
Discovery Phase 1 Phase 2 | ||
| Areas of Focus: SMARCA4 mutated NSCLC and Other cancers | ||
| New Programs (Multiple Targets) | ||
| Selected solid and hematologic malignancies | ||
Discovery Phase 1 Phase 2 | ||
| Areas of Focus: Solid Tumors Heme Malignancies | ||